UBS Maintains CureVac(CVAC.US) With Buy Rating, Cuts Target Price to $12
CureVac Analyst Ratings
UBS Trims Price Target on CureVac to $12 From $13, Maintains Buy Rating
Shares of Vaccine Stocks Are Trading Lower After CDC Advisers Begins a Review of Vaccine Guidelines and Discussed a More Narrow Use of COVID-19 Booster Shots.
Express News | Shares of Vaccine Stocks Are Trading Lower After CDC Advisers Begins a Review of Vaccine Guidelines and Discussed a More Narrow Use of COVID-19 Booster Shots
BofA Securities Initiates CureVac(CVAC.US) With Sell Rating, Announces Target Price $2.5
CureVac Among 3 Promising Penny Stocks To Watch
CureVac's Uncertain Prospects Amid Operational Restructuring and Pipeline Challenges
CureVac N.V. Earnings Call: Financial Strength Amid Challenges
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Cuts Target Price to $10
CureVac | 20-F: FY2024 Annual Report
CureVac's Promising Pipeline and Legal Wins Justify Buy Rating
CureVac Stock (CVAC) Dips Despite Promising Treatment Pipeline
CureVac | 6-K: Report of foreign private issuer (related to financial reporting)
Earnings Call Summary | CureVac(CVAC.US) Q4 2024 Earnings Conference
CureVac Reaffirms Expected Cash Runway Into 2028
Express News | CureVac Q4 Sales €14.50M May Not Be Comparable To €6.50M Estimate
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Express News | CureVac NV - Part B of Gliosblastoma Study First Data Readout Anticipated in H2 2025
Express News | CureVac NV - Jury Trial in U.S. Litigation Postponed to September 8, 2025